磺达肝癸钠五糖减轻狒狒大肠杆菌脓毒症凝血病并提高生存率
该研究在致死性大肠杆菌脓毒症狒狒模型中,比较单纯菌血症与加用磺达肝癸钠(FPX)的效果。
要点
- FPX抑制凝血酶生成上游,降低FXIa-AT、FVIIa-AT、FXa-AT和TAT复合物。
- FPX减轻纤维蛋白原消耗、纤维蛋白生成与降解、中性粒细胞与补体激活及细胞因子产生。
- FPX改善器官功能并提高生存率,血小板计数未受影响。
核心结论
- FPX介导的凝血抑制可预防脓毒症凝血病,减轻过度补体激活与炎症,改善器官功能障碍并带来生存获益。
研究设计与样本
- 研究采用狒狒致死性大肠杆菌脓毒症模型,设单纯大肠杆菌攻击组(n=4)和大肠杆菌加FPX组(n=4)。
- 菌血症通过静脉输注病原体(1-2×10^10 CFU/kg)建立。
- FPX(0.08 mg/kg)在细菌输注前3小时及后8小时皮下给药。
主要发现
- 菌血症迅速增加抗凝血酶与凝血蛋白酶抑制复合物的血浆水平。
- FPX治疗组内源(FXIa-AT)和外源(FVIIa-AT)通路激活标志物显著降低。
- FXa-AT和TAT复合物在攻击后4至8小时达峰值,FPX治疗组降低超过50%。
- 脓毒症强烈诱导纤维蛋白原消耗、纤维蛋白生成与降解、中性粒细胞和补体激活及细胞因子产生,上述参数均显著降低,而血小板计数不变。
临床怎么用
- 在脓毒症相关凝血病中,可考虑靶向凝血酶生成上游的FPX类抗凝策略,但需临床研究验证。
- 治疗期间需监测凝血激活标志物及器官功能,血小板计数可不作为主要调整依据。
局限性
- 研究为狒狒模型,样本量小(每组n=4),结果不能直接外推至人类。
- 给药方案为固定时间点皮下注射,未探索剂量效应与不同给药时机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sepsis triggers dysfunction of coagulation and fibrinolytic systems leading to disseminated intravascular coagulation (DIC) that contributes to organ failure and death. Fondaparinux (FPX) is a synthetic pentasaccharide that binds to antithrombin (AT) and selectively inhibits factor (F) Xa and other upstream coagulation proteases but not thrombin (T). OBJECTIVES: We used a baboon model of lethal Escherichia coli sepsis to investigate the effects of FPX treatment on DIC, organ function, and outcome. METHODS: Two experimental groups were studied: (a) E. coli challenge (n = 4); and (b) E coli plus FPX (n = 4). Bacteremia was modeled by intravenous infusion of pathogen (1-2 × 1010 CFU/kg). Fondaparinux (0.08 mg/kg) was administered subcutaneously, 3 h prior to and 8 h after bacteria infusion. RESULTS: Bacteremia rapidly increased plasma levels of inhibitory complexes of AT with coagulation proteases. Activation markers of both intrinsic (FXIa-AT), and extrinsic (FVIIa-AT) pathways were significantly reduced in FPX-treated animals. Factor Xa-AT and TAT complexes were maximal at 4 to 8 h post challenge and reduced >50% in FPX-treated animals. Fibrinogen consumption, fibrin generation and degradation, neutrophil and complement activation, and cytokine production were strongly induced by sepsis. All parameters were significantly reduced, while platelet count was unchanged by the treatment. Fondaparinux infusion attenuated organ dysfunction, prolonged survival, and saved two of four challenged animals (log-rank Mantel-Cox test, P = .0067). CONCLUSION: Our data indicate that FPX-mediated inhibition of coagulation prevents sepsis coagulopathy; protects against excessive complement activation, inflammation, and organ dysfunction; and provides survival benefit in E. coli sepsis.
引用
- Keshari RS, Silasi R, Popescu NI, et al. Fondaparinux pentasaccharide reduces sepsis coagulopathy and promotes survival in the baboon model of Escherichia coli sepsis. J Thromb Haemost. 2019. PMID: 31549765. doi:10.1111/jth.14642
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。